Targeting phosphatidylserine in anti-cancer therapy

Curr Pharm Des. 2009;15(23):2719-23. doi: 10.2174/138161209788923903.

Abstract

Targeted delivery of cytotoxic agents limits the severe toxic side-effects of anti-cancer drugs on healthy tissues. Annexin A5 is a well explored probe to target phosphatidylserine (PS)-expressing cells in vivo. Our novel understanding of the cellular and molecular mechanism of annexin A5 as a cell-entry agent and the finding that PS is expressed on living tumour as well as endothelial cells in the tumour vasculature, will allow the development of lead compounds for anti-cancer therapy.

Publication types

  • Review

MeSH terms

  • Animals
  • Annexin A5 / pharmacology
  • Annexin A5 / therapeutic use
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Apoptosis / drug effects
  • Apoptosis / immunology
  • Biomarkers
  • Drug Delivery Systems / methods*
  • Humans
  • Models, Biological
  • Neoplasms / drug therapy*
  • Phosphatidylserines / antagonists & inhibitors*
  • Phosphatidylserines / metabolism
  • Phosphatidylserines / physiology
  • Phosphatidylserines / therapeutic use*

Substances

  • Annexin A5
  • Antineoplastic Agents
  • Biomarkers
  • Phosphatidylserines